Deucravacitinib Adherence Study

Description

Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.

Conditions

Psoriasis

Talk to us

Study Overview

On this page

Study Details

Study overview

Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.

Deucravacitinib Adherence Study

Deucravacitinib Adherence Study

Condition
Psoriasis
Intervention / Treatment

-

Contacts and Locations

Winston-Salem

Wake Forest University Health Sciences Department of Dermatology, Winston-Salem, North Carolina, United States, 27157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with moderate-to-severe plaque psoriasis. Standard criteria for moderate-to-severe plaque psoriasis will be used (BSA greater than or equal to 3% or face/palm/sole/genital involvement or severe effect on Quality of Life).
  • * Subject must be 18 years of age or older.
  • * Subject must have a working knowledge of English.
  • * Approved birth control methods required for females of childbearing potential.
  • * Baseline TB test.
  • * Patients without a diagnosis of moderate-to-severe plaque psoriasis.
  • * Patients under 18 years of age.
  • * Patients with severe or unstable comorbid conditions.
  • * Patients with active malignancy or malignancy in past 5 years (not including appropriately treated cutaneous basal and cutaneous-limited squamous cell carcinomas).
  • * Patients who are pregnant or breastfeeding.
  • * Patients with any other skin condition that prohibit or confound the ability of the investigator to interpret skin findings.
  • * Patients with active substance or alcohol abuse disorder; or history of substance/alcohol abuse disorder within 6 months prior to study enrollment.
  • * History of, or active, severe depression and/or suicidality.
  • * Patients with active or latent tuberculosis as determined by quant-TB baseline testing
  • * Patients that are taking concomitant biologics, systemics for the treatment of psoriasis and/or phototherapy.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Steven R Feldman, MD, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

2025-03